Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 10/10

vs
industry
vs
history
Cash-to-Debt No Debt
NAS:FPRX's Cash-to-Debt is ranked higher than
76% of the 943 Companies
in the Global Biotechnology industry.

( Industry Median: 54.02 vs. NAS:FPRX: No Debt )
Ranked among companies with meaningful Cash-to-Debt only.
NAS:FPRX' s Cash-to-Debt Range Over the Past 10 Years
Min: N/A  Med: No Debt Max: No Debt
Current: No Debt
N/A
No Debt
Equity-to-Asset 0.87
NAS:FPRX's Equity-to-Asset is ranked higher than
78% of the 709 Companies
in the Global Biotechnology industry.

( Industry Median: 0.67 vs. NAS:FPRX: 0.87 )
Ranked among companies with meaningful Equity-to-Asset only.
NAS:FPRX' s Equity-to-Asset Range Over the Past 10 Years
Min: -2.63  Med: 0.63 Max: 0.87
Current: 0.87
-2.63
0.87
Interest Coverage No Debt
NAS:FPRX's Interest Coverage is ranked higher than
67% of the 453 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. NAS:FPRX: No Debt )
Ranked among companies with meaningful Interest Coverage only.
NAS:FPRX' s Interest Coverage Range Over the Past 10 Years
Min: No Debt  Med: No Debt Max: No Debt
Current: No Debt
Piotroski F-Score: 3
Altman Z-Score: 11.42
Beneish M-Score: 16.72
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 2/10

vs
industry
vs
history
Operating Margin % -323.26
NAS:FPRX's Operating Margin % is ranked lower than
65% of the 737 Companies
in the Global Biotechnology industry.

( Industry Median: -92.31 vs. NAS:FPRX: -323.26 )
Ranked among companies with meaningful Operating Margin % only.
NAS:FPRX' s Operating Margin % Range Over the Past 10 Years
Min: -323.26  Med: -195.38 Max: 75.56
Current: -323.26
-323.26
75.56
Net Margin % -214.06
NAS:FPRX's Net Margin % is ranked lower than
61% of the 737 Companies
in the Global Biotechnology industry.

( Industry Median: -79.00 vs. NAS:FPRX: -214.06 )
Ranked among companies with meaningful Net Margin % only.
NAS:FPRX' s Net Margin % Range Over the Past 10 Years
Min: -276.42  Med: -194.6 Max: 65.73
Current: -214.06
-276.42
65.73
ROE % -15.77
NAS:FPRX's ROE % is ranked higher than
64% of the 853 Companies
in the Global Biotechnology industry.

( Industry Median: -36.35 vs. NAS:FPRX: -15.77 )
Ranked among companies with meaningful ROE % only.
NAS:FPRX' s ROE % Range Over the Past 10 Years
Min: -52.26  Med: -15.93 Max: 96.31
Current: -15.77
-52.26
96.31
ROA % -13.31
NAS:FPRX's ROA % is ranked higher than
65% of the 950 Companies
in the Global Biotechnology industry.

( Industry Median: -29.87 vs. NAS:FPRX: -13.31 )
Ranked among companies with meaningful ROA % only.
NAS:FPRX' s ROA % Range Over the Past 10 Years
Min: -53.75  Med: -22.36 Max: 70.93
Current: -13.31
-53.75
70.93
ROC (Joel Greenblatt) % -1852.01
NAS:FPRX's ROC (Joel Greenblatt) % is ranked lower than
70% of the 907 Companies
in the Global Biotechnology industry.

( Industry Median: -394.49 vs. NAS:FPRX: -1852.01 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
NAS:FPRX' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -1852.01  Med: -624.88 Max: 6887.63
Current: -1852.01
-1852.01
6887.63
3-Year Revenue Growth Rate -23.00
NAS:FPRX's 3-Year Revenue Growth Rate is ranked lower than
77% of the 507 Companies
in the Global Biotechnology industry.

( Industry Median: 5.10 vs. NAS:FPRX: -23.00 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
NAS:FPRX' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: 0  Med: -46.5 Max: 19
Current: -23
0
19
GuruFocus has detected 3 Warning Signs with Five Prime Therapeutics Inc $NAS:FPRX.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» NAS:FPRX's 10-Y Financials

Financials (Next Earnings Date: 2017-08-04 Est.)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q1 2016

FPRX Guru Trades in Q1 2016

Joel Greenblatt 112,967 sh (New)
RS Investment Management 594,550 sh (+16.31%)
Paul Tudor Jones 15,120 sh (+15.55%)
Jim Simons 233,300 sh (-25.51%)
» More
Q2 2016

FPRX Guru Trades in Q2 2016

Steven Cohen 19,200 sh (New)
Joel Greenblatt 241,475 sh (+113.76%)
RS Investment Management 539,193 sh (-9.31%)
Paul Tudor Jones 12,300 sh (-18.65%)
Jim Simons 121,300 sh (-48.01%)
» More
Q3 2016

FPRX Guru Trades in Q3 2016

John Hussman 125,000 sh (New)
Steven Cohen Sold Out
Paul Tudor Jones 6,600 sh (-46.34%)
Jim Simons 51,700 sh (-57.38%)
Joel Greenblatt 13,421 sh (-94.44%)
» More
Q4 2016

FPRX Guru Trades in Q4 2016

Jim Simons Sold Out
John Hussman 115,000 sh (-8.00%)
Joel Greenblatt 11,150 sh (-16.92%)
Paul Tudor Jones 5,123 sh (-22.38%)
» More
» Details

Insider Trades

Latest Guru Trades with NAS:FPRX

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology    NAICS: 325412    SIC: 2834
Compare:NAS:ALDR, OTCPK:PFSCF, NAS:CHRS, NAS:AIMT, NAS:ASND, NAS:EPZM, OTCPK:MEOBF, NAS:ZIOP, NAS:FWP, OTCPK:GNFTF, NAS:CORT, OTCPK:BPMUF, NAS:JNCE, NAS:FOLD, NAS:CLCD, NAS:AMRN, NAS:AKAO, NAS:INSM, OTCPK:CMVLF, NAS:AMAG » details
Traded in other countries:5P8.Germany,
Headquarter Location:USA
Five Prime Therapeutics Inc is a clinical-stage biotechnology company. It is engaged in discovering & developing novel protein therapeutics to improve lives of patients with serious diseases. Its products include FP-1039/GSK3052230, FPA008 & FPA144.

Five Prime Therapeutics is a biotechnology company focused on discovering and developing protein therapeutics for diseases. The company's product candidates address patient populations for which therapies are still needed. Its is focused on advancing its internal pipeline and retaining rights for products in targeted specialty markets. It also seeks to establish additional collaborations to supplement its internal development capabilities. These collaborations generate additional funding in order to further validate the company's technology.

Ratios

vs
industry
vs
history
PB Ratio 2.50
FPRX's PB Ratio is ranked higher than
64% of the 844 Companies
in the Global Biotechnology industry.

( Industry Median: 3.75 vs. FPRX: 2.50 )
Ranked among companies with meaningful PB Ratio only.
FPRX' s PB Ratio Range Over the Past 10 Years
Min: 1.77  Med: 3.33 Max: 8.42
Current: 2.5
1.77
8.42
PS Ratio 30.47
FPRX's PS Ratio is ranked lower than
71% of the 685 Companies
in the Global Biotechnology industry.

( Industry Median: 12.47 vs. FPRX: 30.47 )
Ranked among companies with meaningful PS Ratio only.
FPRX' s PS Ratio Range Over the Past 10 Years
Min: 0.99  Med: 5.16 Max: 50.27
Current: 30.47
0.99
50.27
EV-to-EBIT -6.81
FPRX's EV-to-EBIT is ranked lower than
99.99% of the 423 Companies
in the Global Biotechnology industry.

( Industry Median: 22.87 vs. FPRX: -6.81 )
Ranked among companies with meaningful EV-to-EBIT only.
FPRX' s EV-to-EBIT Range Over the Past 10 Years
Min: -13.8  Med: -4.2 Max: 4.6
Current: -6.81
-13.8
4.6
EV-to-EBITDA -6.95
FPRX's EV-to-EBITDA is ranked lower than
99.99% of the 466 Companies
in the Global Biotechnology industry.

( Industry Median: 17.12 vs. FPRX: -6.95 )
Ranked among companies with meaningful EV-to-EBITDA only.
FPRX' s EV-to-EBITDA Range Over the Past 10 Years
Min: -14.2  Med: -4.4 Max: 4.5
Current: -6.95
-14.2
4.5
Current Ratio 11.36
FPRX's Current Ratio is ranked higher than
82% of the 921 Companies
in the Global Biotechnology industry.

( Industry Median: 4.05 vs. FPRX: 11.36 )
Ranked among companies with meaningful Current Ratio only.
FPRX' s Current Ratio Range Over the Past 10 Years
Min: 2.99  Med: 6.14 Max: 11.36
Current: 11.36
2.99
11.36
Quick Ratio 11.36
FPRX's Quick Ratio is ranked higher than
83% of the 920 Companies
in the Global Biotechnology industry.

( Industry Median: 3.77 vs. FPRX: 11.36 )
Ranked among companies with meaningful Quick Ratio only.
FPRX' s Quick Ratio Range Over the Past 10 Years
Min: 2.99  Med: 6.14 Max: 11.36
Current: 11.36
2.99
11.36
Days Sales Outstanding 102.62
FPRX's Days Sales Outstanding is ranked lower than
72% of the 596 Companies
in the Global Biotechnology industry.

( Industry Median: 61.11 vs. FPRX: 102.62 )
Ranked among companies with meaningful Days Sales Outstanding only.
FPRX' s Days Sales Outstanding Range Over the Past 10 Years
Min: 3.9  Med: 7.81 Max: 102.62
Current: 102.62
3.9
102.62

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -19.30
FPRX's 3-Year Average Share Buyback Ratio is ranked lower than
70% of the 571 Companies
in the Global Biotechnology industry.

( Industry Median: -11.10 vs. FPRX: -19.30 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
FPRX' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -179.4  Med: -72.15 Max: 0
Current: -19.3
-179.4
0

Valuation & Return

vs
industry
vs
history
Price-to-Net-Cash 2.73
FPRX's Price-to-Net-Cash is ranked higher than
78% of the 514 Companies
in the Global Biotechnology industry.

( Industry Median: 6.54 vs. FPRX: 2.73 )
Ranked among companies with meaningful Price-to-Net-Cash only.
FPRX' s Price-to-Net-Cash Range Over the Past 10 Years
Min: 2.59  Med: 4.68 Max: 7.44
Current: 2.73
2.59
7.44
Price-to-Net-Current-Asset-Value 2.60
FPRX's Price-to-Net-Current-Asset-Value is ranked higher than
79% of the 630 Companies
in the Global Biotechnology industry.

( Industry Median: 6.07 vs. FPRX: 2.60 )
Ranked among companies with meaningful Price-to-Net-Current-Asset-Value only.
FPRX' s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 2.46  Med: 4.5 Max: 7.24
Current: 2.6
2.46
7.24
Price-to-Tangible-Book 2.55
FPRX's Price-to-Tangible-Book is ranked higher than
71% of the 769 Companies
in the Global Biotechnology industry.

( Industry Median: 4.58 vs. FPRX: 2.55 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
FPRX' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 2.41  Med: 4.27 Max: 6.87
Current: 2.55
2.41
6.87
Price-to-Median-PS-Value 5.92
FPRX's Price-to-Median-PS-Value is ranked lower than
96% of the 584 Companies
in the Global Biotechnology industry.

( Industry Median: 0.98 vs. FPRX: 5.92 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
FPRX' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.46  Med: 3.23 Max: 8.82
Current: 5.92
0.46
8.82
Earnings Yield (Greenblatt) % -14.66
FPRX's Earnings Yield (Greenblatt) % is ranked lower than
71% of the 1272 Companies
in the Global Biotechnology industry.

( Industry Median: -6.37 vs. FPRX: -14.66 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
FPRX' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -16.05  Med: 45.35 Max: 212.2
Current: -14.66
-16.05
212.2

More Statistics

Revenue (TTM) (Mil) $30.69
EPS (TTM) $ -2.44
Beta4.67
Short Percentage of Float9.55%
52-Week Range $31.79 - 60.98
Shares Outstanding (Mil)28.77

Analyst Estimate

Dec17
Revenue (Mil $)
EPS ($) -4.94
EPS without NRI ($) -4.94
EPS Growth Rate
(Future 3Y To 5Y Estimate)
N/A
Dividends per Share ($)
» More Articles for NAS:FPRX

Headlines

Articles On GuruFocus.com
Five Prime to Present Clinical Data at 2017 ASCO Annual Meeting Apr 20 2017 
Five Prime Therapeutics to Announce First Quarter 2017 Financial Results and Host Conference Call on Apr 20 2017 
Five Prime Therapeutics Announces Completion of Enrollment for the Phase 2 Part of the Ongoing Trial Apr 10 2017 
Five Prime Presents Data on Unique Immuno-Oncology Discovery Research at the 2017 AACR Annual Meetin Apr 03 2017 
Five Prime Presents Preclinical Research Data on CSF-1R and PD-1 Blockade at the 2017 AACR Annual Me Apr 03 2017 
Five Prime Presents Preclinical Research Data on Novel Tetravalent Anti-GITR Antibody at 2017 AACR A Apr 02 2017 
Five Prime Therapeutics Announces Executive Changes Mar 20 2017 
5 Mid-Cap Stocks With Low Enterprise Multiples Aug 03 2016 
Weekly CEO Sales Highlight: Monolithic Power Systems, Five Prime Therapeutics, Nektar Therapeutics Feb 15 2016 
Value Investing in BioPharma Nov 18 2015 

More From Other Websites
Five Prime to Present Clinical Data at 2017 ASCO Annual Meeting Apr 20 2017
Five Prime Therapeutics to Announce First Quarter 2017 Financial Results and Host Conference Call on... Apr 20 2017
Five Prime Therapeutics Announces Completion of Enrollment for the Phase 2 Part of the Ongoing Trial... Apr 10 2017
Five Prime Presents Data on Unique Immuno-Oncology Discovery Research at the 2017 AACR Annual... Apr 03 2017
Five Prime Presents Preclinical Research Data on CSF-1R and PD-1 Blockade at the 2017 AACR Annual... Apr 03 2017
Five Prime Presents Preclinical Research Data on Novel Tetravalent Anti-GITR Antibody at 2017 AACR... Apr 02 2017
ETFs with exposure to Five Prime Therapeutics, Inc. : March 27, 2017 Mar 27 2017
Five Prime Therapeutics, Inc. :FPRX-US: Earnings Analysis: Q4, 2016 By the Numbers : March 21, 2017 Mar 21 2017
Five Prime Therapeutics Announces Executive Changes Mar 20 2017
Five Prime Therapeutics, Inc. :FPRX-US: Earnings Analysis: 2016 By the Numbers : March 1, 2017 Mar 01 2017
Edited Transcript of FPRX earnings conference call or presentation 23-Feb-17 9:30pm GMT Feb 23 2017
Five Prime Therapeutics posts 4Q loss Feb 23 2017
Five Prime Announces Fourth Quarter and Full Year 2016 Financial Results Feb 23 2017
Five Prime Therapeutics to Announce Fourth Quarter and Full Year 2016 Financial Results and Host... Feb 09 2017
Five Prime Therapeutics to Present at the LEERINK Partners 6th Annual Global Healthcare Conference Feb 08 2017
Five Prime to Present Preclinical Research Data at 2017 AACR Annual Meeting Feb 08 2017
Cabiralizumab From Five Prime Therapeutics Inc (FPRX) Obtains Orphan Designation Jan 25 2017
Blog Coverage Five Prime Announced Extension of Collaboration Agreement by Bristol-Myers Squibb Jan 06 2017
Bristol-Myers Extends Deal with Five Prime Therapeutics Jan 05 2017

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)